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The prostaglandin D2 (PGD2) receptor, CRTH2, plays a role in allergic airway inﬂammation. The efﬁcacy of
BI 671800, a CRTH2 antagonist, was assessed in 2 separate trials in patients with asthma, in either the
absence or the presence of inhaled corticosteroid (ICS) therapy. In this study, BI 671800 (50, 200 or
400 mg) and ﬂuticasone propionate (220 mg) all given twice daily (bid) were compared with bid placebo
in symptomatic controller-naïve adults with asthma (Trial 1), and BI 671800 400 mg bid compared with
montelukast 10 mg once daily (qd), and matching placebo bid, in patients with asthma receiving inhaled
ﬂuticasone (88 mg bid) (Trial 2). The primary endpoint in both trials was change from baseline in trough
forced expiratory volume in 1 s (FEV1) percent predicted. After 6 weeks' treatment, adjusted mean
treatment differences (SE) for the primary endpoint compared with placebo in Trial 1 were 3.08% (1.65%),
3.59% (1.60%) and 3.98% (1.64%) for BI 671800 50, 200 and 400 mg bid, respectively, and 8.62% (1.68%) for
ﬂuticasone 220 mg bid (p ¼ 0.0311, p ¼ 0.0126, p ¼ 0.0078 and p < 0.0001, respectively). In Trial 2,
adjusted mean FEV1 (SE) treatment differences compared with placebo were 3.87% (1.49%) for BI 671800
400 mg bid and 2.37% (1.57%) for montelukast (p ¼ 0.0050 and p ¼ 0.0657, respectively). These ﬁndings
suggest that BI 671800 is associated with a small improvement in FEV1 in symptomatic controller-naïve
asthma patients, and in patients on ICS.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).re; AQLQ, Asthma Quality of
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Asthma is a chronic inﬂammatory disease of the airways,
marked by symptoms attributable to episodic bronchodilator-
responsive airﬂow limitation and airway hyperresponsiveness [1].
Airway inﬂammation in asthma involves a complex interaction of
inﬂammatory mediators, often triggered by an allergen-induced
immunoglobulin E (IgE)-mediated release by mast cells of media-
tors such as histamine, proteases, cytokines and eicosanoids,
including leukotrienes and prostaglandins.
Prostaglandin D2 (PGD2), an arachidonic acid metabolite
important to the pathogenesis of asthma, is released by IgE-
activated mast cells and other inﬂammatory cell types, such asunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Design of (A) Trial 1 (1268.17); (B) Trial 2 (1268.16); FP ¼ ﬂuticasone propionate.
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dendritic cells following allergen exposure. The pro-
inﬂammatory effects of PGD2 occur via interactions with the
chemoattractant receptor homologous molecule on Th2 cells
(CRTH2), a 7-transmembrane G-protein-coupled receptor selec-
tively expressed on Th2 cells, eosinophils and basophils [2e4].
PGD2 chemotactic activity recruits circulating eosinophils and
basophils from the vascular bed to the site of inﬂammation in a
CRTH2-dependent manner. Furthermore, PGD2 has an important
role in the early phase of CRTH2-dependent Th2-cell recruitment
and activation, resulting in the production of cytokines (eg,
interleukin (IL)-4, IL-5, IL-9 and IL-13), which, in turn, further
stimulate mast cells and eosinophils [5]. Thus, inhibition of
CRTH2 may attenuate important inﬂammatory pathways in
asthma, thereby reducing airway inﬂammation and potentially
improving asthma control.
A previous study of the CRTH2 antagonist, OC000459, in corti-
costeroid-naïve individuals with asthma reported a statistically
signiﬁcant improvement in forced expiratory volume in 1 s (FEV1)
in the per-protocol patient group, but not in the intention-to-treat
cohort [6]. A study of a different molecule, a dual DP1 and CRTH2
antagonist, AMG 853, found no improvement in Asthma Control
Questionnaire (ACQ) score or FEV1 [7]. The explanation for these
inconsistent results is unclear, but may relate to differences in the
efﬁcacy of the agents used, variation in trial design, or differences in
receptor selectivity of the 2 compounds.
We hypothesised that inhibition of CRTH2 with BI 671800, a
highly speciﬁc and potent CRTH2 antagonist [8], would result in
improved lung function in adult patients with mild-to-moderate
asthma. Here we report the results of 2 clinical trials e 1 in
controller-naïve patients with symptomatic asthma (study 1268.17;
Trial 1), the other in symptomatic patients taking inhaled cortico-
steroids (study 1268.16; Trial 2) e and provide evidence that
antagonism of CRTH2 can improve lung function in patients with
asthma.2. Methods
2.1. Trial design
We conducted 2 separate clinical trials, both of which were
multicentre, multinational, randomised, double-blind and were
placebo-controlled, parallel-group, double-dummy designs. Trial 1
examined the efﬁcacy, safety and tolerability of 3 doses of BI 671800
(50, 200 or 400mg twice daily) and ﬂuticasone propionate 110 mg 2
inhalations twice daily, compared with matching placebo in
symptomatic steroid-naïve adults with asthma. Trial 2 compared
the efﬁcacy, safety and tolerability of BI 671800 400 mg twice daily
and montelukast 10 mg once daily, with matching placebo twice
daily in patients with asthma taking inhaled ﬂuticasone (88 mg
twice daily).
For both studies, the inclusion criteria were non-smoking (or
ex-smoking) patients with asthma, age 18e65 years with docu-
mented airﬂow reversibility, a pre-bronchodilator FEV1 60e85%
predicted, and an ACQ score 1.5 at randomisation. For Trial 1,
patients were not to have taken an inhaled corticosteroid (ICS) for
6 weeks before screening. For Trial 2, patients had to have been
on a stable dose of ICS for3months before screening; following a
run-in period of 2e4 weeks, patients were randomised if they
were symptomatic despite using inhaled ﬂuticasone propionate
(44 mg, 2 inhalations twice daily) during at least the last 2 weeks of
the run-in period. A summary of the trial designs is shown in
Fig. 1A and B.2.2. Randomisation and masking
The sponsor generated a randomisation list using a validated
system involving a pseudo-random number generator and a sup-
plied seed number. Patients, investigators, and the sponsor
remained blinded with regard to the randomised treatment as-
signments up to database lock, in accordance with the study pro-
tocol. After assessment of all inclusion and exclusion criteria,
eligible patients were assigned a medication number by an Inter-
active Voice Response System at the time of randomisation.
Respective placebos for BI 671800 and montelukast capsules (Trial
2) and for the ﬂuticasone propionate metered dose inhaler (Trial 1)
could not be distinguished by appearance, taste or odour.
2.3. Endpoints
The primary endpoint for both studies was change frombaseline
in trough FEV1 percent predicted at 6 weeks. The secondary
endpoint was change from baseline in ACQ mean score at 6 weeks.
Changes in trough FEV1 percent predicted and ACQ mean score
were analysed in the full analysis set (FAS) using a mixed-effect,
repeated-measures model with terms for baseline, treatment, test
day, treatment by test day interaction, baseline by test day inter-
action as ﬁxed effects and patient as a random effect. Other end-
points included FEV1 percent predicted area under the curve
(AUC)0e3h, forced vital capacity (FVC), forced expiratory ﬂow at
25e75% of FVC (FEF25e75%), morning and evening peak expiratory
ﬂow (PEF), Asthma Quality of Life Questionnaire (AQLQ), short-
acting b-agonist (SABA) use, time to ﬁrst worsening of asthma
and time to ﬁrst exacerbation. In addition to the FAS, a per-protocol
sensitivity analysis was performed for each study.
Both studies were approved by the appropriate ethical review
committees and were registered with ClinicalTrials.gov
(NCT01092148 for Trial 1 and NCT01103349 for Trial 2).
3. Results
In both trials, participant characteristics at baseline were
balanced across treatment groups (Tables 1 and 2).
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inhaled corticosteroid (Trial 1)
A total of 1045 patients were screened; of these, 656 were
screen failures and 389 were randomised: 78 to placebo, 77, 84 and
79 to BI 671800 50, 200 and 400 mg twice daily, respectively, and
71 to ﬂuticasone 220 mg twice daily. A total of 40 participants dis-
continued the trial prematurely (see Fig. 2A for details). Of the 389
randomised participants, 388 received1 dose of studymedication
and were included in the treatment set. A further 15 patients had
either no baseline or on-treatment trough FEV1 data, resulting in
373 patients being included in the FAS.
3.2. Effects on lung function (Trial 1)
After 6 weeks of treatment, the adjusted mean treatment
differences (SE) compared with placebo for trough FEV1 were
3.08% (1.65%), 3.59% (1.60%) and 3.98% (1.64%) for 50, 200 and
400 mg twice daily, respectively, and 8.62% (1.68%) for ﬂutica-
sone 220 mg twice daily (Fig. 3A). Versus placebo, these differ-
ences were statistically signiﬁcant (at the 2.5% level) for all
treatment groups with the exception of the 50 mg twice-daily
group: (1-sided p-values were 0.0311, 0.0126, 0.0078 and
p < 0.0001, respectively). Compared with ﬂuticasone 220 mg
twice daily, the adjusted mean treatment differences (SE) after 6
weeks were 5.54% (1.65%), 5.03% (1.61%) and 4.64% (1.65%)
for the 50, 200 and 400 mg twice daily treatment arms,
respectively. These differences, in favour of ﬂuticasone, were
statistically signiﬁcant at the 5% signiﬁcance level (post hoc
analysis); 2-sided p-values were 0.0009, 0.0018 and 0.0050,
respectively. The corresponding adjusted mean absolute differ-
ence in trough FEV1 between BI 671800 400 mg and placebo was
134 mL, and 293 mL for ﬂuticasone 220 mg compared with pla-
cebo. A post hoc subgroup analysis was conducted on groups
deﬁned by peripheral blood eosinophil counts. A greater
improvement in FEV1 was noted in patients with an eosinophil
count of >350 cells/mm3 in patients dosed with 200 and 400 mg
bid (200 mg bid: increase of 2.85 FEV1 % predicted vs. baseline
for patients with eosinophils >350 cells/mm3, n ¼ 30, compared
to 0.64% for patients with <350 cells/mm3, n ¼ 51; 400 mg bid:
4.38% increase vs. baseline for patients with eosinophils >350
cells/mm3, n ¼ 17, compared to 1.35% for patients with <350
cells/mm3, n ¼ 54. Eosinophil data were not available for 6
subjects.Table 1
Baseline characteristics (Trial 1).
Treatment arm Placebo BI 671800 50 mg
twice daily
BI
tw
n 78 77 83
Age, years 36.4 (13.0) 39.1 (11.5) 35
Female, % 47.4 53.2 50
BMI 26.4 (4.7) 27.0 (4.6) 25
Allergic asthma, n (%) 59 (75.6) 58 (75.3) 65
FEV1, percent predicted 72.7 (6.5) 71.4 (7.3) 73
FEV1, L 2.52 (0.63) 2.41 (0.62) 2.
FEV1 at screening, L 2.47 (0.70) 2.32 (0.66) 2.
FEV1/FVC ratio, % 68.7 (10.0) 67.1 (10.6) 67
Weekly mean SABA use, puffs/day 2.9 (2.7) 3.0 (2.7) 2.
ACQ score 2.2 (0.6) 2.3 (0.6) 2.
Weekly mean morning PEF, L/min 378.0 (114.6) 380.8 (124.1) 37
No LABA use, n (%) 65 (83.3) 65 (84.4) 67
Data expressed as mean (SD) unless otherwise stated; ACQ¼ Asthma Control Questionna
propionate; FVC ¼ forced vital capacity; LABA ¼ long-acting b2-agonist; PEF ¼ peak exp3.3. Effects on asthma control and on exploratory endpoints (Trial
1)
No statistically signiﬁcant effect (at the 1-sided 2.5% level) of BI
671800 was observed on asthma control (ACQ). In contrast, FP
220 mg twice daily was associated with a statistically signiﬁcant
improvement in ACQ. Some exploratory endpoints demonstrated
statistical signiﬁcant improvements with BI 671800 (at the 1-sided
2.5% level): FEV1 percent predicted AUC0e3h, trough FEV1, FEV1
AUC0e3h, trough FEF and morning PEF (Table 3). Besides the
improvement in pulmonary function, the highest dose tested for BI
671800, 400 mg twice daily, also associated prolonged the time to
the ﬁrst asthma worsening compared with placebo (hazard ratio
[HR] 0.45, p ¼ 0.0074), an efﬁcacy similar to that seen in the ﬂuti-
casone arm (HR 0.33, p ¼ 0.0015).3.4. Safety and tolerability (Trial 1)
BI 671800 was safe and well tolerated at all doses evaluated.
There were no differences in adverse events across treatment
groups. Only 2 serious adverse events were reported (1 in the
placebo group, 1 in the BI 678100 400-mg dose group). Neither
event was considered study drug related. There were more dis-
continuations due to an adverse event in the placebo group
compared with any active treatment group, primarily due to
worsening of asthma. A full list of adverse events is reported in
Supplementary Table S1. Four patients taking BI 671800 had small
elevations of hepatic transaminases that were maximally <6 ULN
(upper limit of normal).3.5. Efﬁcacy of BI 671800 in patients with asthma taking an inhaled
corticosteroid (Trial 2)
A total of 647 patients were screened; of these, 404 were
screen failures, and 243 were randomised: 95 to placebo, 81 to BI
671800 400 mg twice daily and 67 to montelukast 10 mg once
daily. All continued on inhaled ﬂuticasone 88 mg twice daily. All
243 randomised patients received 1 dose of study medication
and were included in the treated set. A total of 22 participants
discontinued the trial prematurely (see Fig. 2B for details).
Thirteen patients had either no baseline or no on-treatment
trough FEV1 data, resulting in only 230 patients being included
in the FAS.671800 200 mg
ice daily
BI 671800 400 mg
twice daily
FP 220 mg
twice daily
Total
79 71 388
.1 (11.1) 37.5 (12.2) 39.4 (12.2) 37.4 (12.1)
.6 54.4 50.7 51.3
.9 (4.3) 26.5 (4.7) 26.7 (4.6) 26.5 (4.5)
(78.3) 67 (84.8) 56 (78.9) 305 (78.6)
.3 (7.3) 73.6 (6.9) 72.3 (6.9) 72.7 (7.0)
60 (0.65) 2.49 (0.65) 2.42 (0.55) 2.49 (0.62)
60 (0.68) 2.42 (0.64) 2.36 (0.59) 2.46 (0.65)
.4 (8.5) 68.2 (9.7) 68.1 (8.8) 67.9 (9.5)
7 (2.8) 3.0 (2.7) 2.8 (2.4) 2.9 (2.7)
3 (0.6) 2.3 (0.5) 2.4 (0.6) 2.3 (0.6)
4.1 (120.9) 381.5 (116.3) 370.0 (118.6) 377.0 (118.4)
(80.7) 60 (75.9) 56 (78.9) 313 (80.7)
ire; BMI¼ body mass index; FEV1¼ forced expiratory volume in 1 s; FP¼ ﬂuticasone
iratory ﬂow; SABA ¼ short-acting b2-agonist; SD ¼ standard deviation.
Fig. 2. CONSORT diagrams for Trial 1 (A) and Trial 2 (B). Patients may have >1 reason for exclusion; FAS ¼ full analysis set; FEV1 ¼ forced expiratory volume in 1 s; PPS ¼ per-
protocol set.
Table 2
Baseline characteristics (Trial 2).
Treatment arm Placebo BI 671800 400 mg twice daily Montelukast 10 mg twice daily Total
n 95 81 67 243
Age, years 41.4 (12.6) 41.8 (12.7) 41.7 (12.0) 41.6 (12.4)
Female, % 57.9 61.7 62.7 60.5
BMI 26.8 (4.3) 27.6 (4.1) 26.7 (4.1) 27.0 (4.2)
Allergic asthma, n (%) 73 (76.8) 67 (82.7) 47 (70.1) 187 (77.0)
FEV1, percent predicted 72.1 (7.3) 72.6 (7.6) 72.3 (7.2) 72.3 (7.3)
FEV1, L 2.49 (0.55) 2.49 (0.59) 2.42 (0.61) 2.47 (0.58)
FEV1 at screening, L 2.35 (0.63) 2.39 (0.70) 2.32 (0.63) 2.36 (0.65)
FEV1/FVC ratio, % 65.0 (10.8) 65.8 (10.1) 65.5 (8.9) 65.4 (10.0)
Weekly mean SABA use, puffs/day 1.9 (2.1) 1.7 (1.8) 1.8 (1.9) 1.8 (1.9)
ACQ score 2.2 (0.5) 2.1 (0.5) 2.0 (0.5) 2.1 (0.5)
Weekly mean morning PEF, L/min 353.4 (121.8) 363.3 (118.2) 345.7 (115.6) 354.6 (118.6)
No LABA use, n (%) 55 (57.9) 49 (60.5) 37 (55.2) 141 (58.0)
Data expressed as mean (SD) unless otherwise stated; ACQ¼ Asthma Control Questionnaire; BMI¼ body mass index; FEV1¼ forced expiratory volume in 1 s; FP¼ ﬂuticasone
propionate; FVC ¼ forced vital capacity; LABA ¼ long-acting b2-agonist; PEF ¼ peak expiratory ﬂow; SABA ¼ short-acting b2-agonist; SD ¼ standard deviation.
Fig. 2. (continued).
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After 6 weeks of treatment, the adjusted mean treatment dif-
ference (SE) for change from baseline in trough FEV1 percent pre-
dicted versus placebo was 3.87% (1.49%) for BI 671800 (1-sided p-
value was 0.0050), but not statistically signiﬁcant for montelukast
(Fig. 3B). Compared with montelukast, the adjusted mean treat-
ment difference (SE) after 6 weeks was 1.50% (1.60%). This differ-
ence was not statistically signiﬁcant (p ¼ 0.1748). The
corresponding adjusted mean absolute difference in trough FEV1
between BI 671800 and placebo was 142 mL, and 80 mL for mon-
telukast compared with placebo. In the post hoc subgroup analysis
of peripheral blood eosinophil counts, an increase in FEV1 % pre-
dicted of 5.06% was observed in the high eosinophil group (n ¼ 24)compared to 2.33% in the lower eosinophil group (n ¼ 50). Eosin-
ophil data were not available for 3 subjects in this study.
3.7. Effects on asthma control and other endpoints (Trial 2)
The adjusted mean (SE) treatment difference for change from
baseline in mean ACQ score versus placebo after 6 weeks of treat-
ment was 0.28 (0.12) for BI 671800 (1-sided p-value was 0.0092)
but was not statistically signiﬁcant for montelukast. The in-clinic
spirometry assessments, including FEV1 percent predicted
AUC0e3h, trough FEV1, FEV1 AUC0e3h and trough FEF, showed BI
671800 400 mg to be statistically signiﬁcantly superior to placebo
at Week 6. These and other endpoint results are presented in
Table 4. The effects on asthma worsening for BI 671800 (HR 0.75)
Fig. 3. Adjusted change from baseline in trough FEV1 percent predicted at 2, 4 and 6
weeks in (A) corticosteroid-naïve patients with uncontrolled asthma treated with
different doses of BI 671800, ﬂuticasone propionate or placebo (Trial 1) and (B) pa-
tients on inhaled corticosteroids with uncontrolled asthma treated with BI 671800,
montelukast or placebo (Trial 2); FEV1 ¼ forced expiratory volume in 1 s;
FP ¼ ﬂuticasone propionate.
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(p ¼ 0.2002 and p ¼ 0.4940, respectively).3.8. Safety and tolerability (Trial 2)
BI 671800 was safe and well tolerated at all doses evaluated.
There were no signiﬁcant differences in adverse events across
treatment groups (see Supplementary Table S2). However, 1 serious
adverse event of toxic hepatitis (raised liver transaminases, but no
change in total bilirubin) was reported in a patient taking BI 671800
and was considered related to the drug. The patient already had
raised transaminases during the run-in that had recovered prior to
randomisation. Three additional patients taking BI 671800 and 1
patient taking montelukast also had small (maximally <8  ULN)
reversible rises in hepatic transaminase levels.4. Discussion
Many pro-inﬂammatory effects of PGD2 are mediated in the
airway through interaction with the CRTH2 receptor expressed on
Th2 cells, eosinophils and basophils [2e4]. We present here the
results of 2 clinical trials designed to study the efﬁcacy and safety ofan oral CRTH2 antagonist, BI 671800, in patients with symptomatic
asthma in the presence or absence of ICS therapy. The data pre-
sented from study Trial 1 demonstrate that BI 671800, when
administered to controller therapy-naïve patients with mild-to-
moderate asthma at either 200 or 400 mg twice daily, produces a
statistically signiﬁcant improvement in trough FEV1 percent pre-
dicted compared with placebo (4.0% with the higher dose, equiv-
alent to 134 mL). This response was less than that observed with
moderate doses of ﬂuticasone (8.6% improvement in trough FEV1
percent predicted, equivalent to 293 mL) and was not accompanied
by an improvement in asthma control. However, a number of
exploratory endpoints also demonstrated improvements: FEV1
percent predicted AUC0e3h, trough FEV1, FEV1 AUC0e3h, trough
FEF25e75%, morning PEF and time to asthma worsening.
In Trial 2, add-on therapy with BI 671800 400 mg twice daily in
patients taking inhaled ﬂuticasone (88 mg twice daily) also resulted
in a statistically signiﬁcant improvement in trough FEV1 percent
predicted compared with placebo (3.9%, equivalent to 142 mL)e an
improvement larger than that demonstrated for montelukast (1.5%,
equivalent to 80 mL), although the difference between BI 671800
andmontelukast was not statistically signiﬁcant. This improvement
in lung function was accompanied by a modest but statistically
signiﬁcant improvement in mean ACQ score.
Between them, these studies include the largest number of
patients with asthma in which the efﬁcacy of CRTH2 antagonists
has been assessed. The data presented here provide proof of
concept that CRTH2 antagonism can play a beneﬁcial role in the
management of asthma, with the effect size for improvement in
trough FEV1 percent predicted being numerically (but not statisti-
cally) greater than that seen with the CysLTR1 antagonist mon-
telukast when used in conjunction with ICS therapy. It should be
noted that Trial 2 was not powered to investigate the effect of BI
671800 relative to montelukast.
Overall, the improvements in trough FEV1 percent predicted
produced by BI 671800 in Trial 1, although statistically signiﬁcant,
were smaller than those seenwith ﬂuticasone. However, the effects
of BI 671800 on asthma worsening were similar to those of ﬂuti-
casone in the controller-naïve population. The observed changes in
pulmonary function are also similar to those reported previously
with the CysLTR1 antagonist montelukast in corticosteroid-naïve
patients with asthma [9]. Side effects were not notably different
between treatment groups in our studies, with the exception of a
small (and reversible) rise in hepatic transaminases observed in 4
patients in Trial 1 taking BI 671800, and 5 patients in Trial 2, 4 of
whom were taking BI 671800. No patient with increases in liver
transaminases had a concomitant rise in total bilirubin. One subject
in Trial 2 taking BI 671800 developed increases in liver trans-
aminases, described by the investigator as a toxic hepatitis thought
to be related to the drug. However, as the affected individual had
elevated transaminases at recruitment that recovered during run-
in before randomisation, it remains unclear whether the observed
hepatitis was causally related to administration of the study drug.
Previously reported studies of the effect of CRTH2 antagonists
on asthma control have provided conﬂicting results. In the study of
OC000459 in steroid-naïve patients with asthma, the CRTH2
antagonist achieved a statistically signiﬁcant improvement in the
FEV1 in the per-protocol analysis compared with placebo (7.66%
predicted [95% conﬁdence interval (CI): 0.49e14.82] or 200mL) but
not in the intention-to-treat population (2.44% predicted [95% CI:
4.42e9.31] or 80 mL) [6]. A separate study of OC000459 resulted in
attenuation of the late-phase, but not the early-phase, response to
allergen challenge following bronchial challenge in sensitive in-
dividuals [10]. Studies performed in patients sensitive to grass
pollen [11] have also demonstrated that OC000459 can reduce
nasal and ocular symptoms. In contrast, the dual DP1 and CRTH2
Table 3
Secondary and exploratory endpoints after 6 weeks of treatment (Trial 1).
Comparison to placebo BI 671800 50 mg twice daily BI 671800 200 mg twice daily BI 671800 400 mg twice daily FP 220 mg twice daily
ACQ score 0.07 (0.11) 0.08 (0.11) 0.06 (0.11) 0.33 (0.12)
p ¼ 0.7413 p ¼ 0.2335 p ¼ 0.2933 p ¼ 0.0021
FEV1 percent predicted AUC0e3h, L 2.65 (1.67) 3.54 (1.59) 3.81 (1.64) 7.83 (1.69)
p ¼ 0.0564 p ¼ 0.0135 p ¼ 0.0106 p < 0.0001
FEV1 trough, L 0.11 (0.06) 0.11 (0.06) 0.13 (0.06) 0.29 (0.06)
p ¼ 0.0273 p ¼ 0.0242 p ¼ 0.0091 p < 0.0001
FEV1 AUC0e3h, L 0.09 (0.06) 0.10 (0.05) 0.13 (0.06) 0.27 (0.06)
p ¼ 0.0566 p ¼ 0.0376 p ¼ 0.0129 p < 0.0001
FVC trough, L 0.13 (0.06) 0.06 (0.06) 0.02 (0.06) 0.18 (0.06)
p ¼ 0.0140 p ¼ 0.1336 p ¼ 0.3343 p ¼ 0.0013
FEF25e75 trough, L/s 0.09 (0.09) 0.11 (0.08) 0.17 (0.09) 0.36 (0.09)
p ¼ 0.1560 p ¼ 0.0981 p ¼ 0.0216 p < 0.0001
Morning PEF, L/min 16.3 (8.1) 11.0 (7.8) 21.5 (8.0) 26.9 (8.2)
p ¼ 0.0221 p ¼ 0.0803 p ¼ 0.0038 p ¼ 0.0006
Evening PEF, L/min 16.8 (7.9) 14.2 (7.6) 14.3 (7.8) 17.7 (8.0)
p ¼ 0.0163 p ¼ 0.0315 p ¼ 0.0340 p ¼ 0.0136
AQLQ score 0.06 (0.14) 0.07 (0.13) 0.15 (0.13) 0.27 (0.14)
p ¼ 0.6571 p ¼ 0.3064 p ¼ 0.1340 p ¼ 0.0254
Time to ﬁrst asthma worsening, HR (95% CI) 0.94 (0.54e1.64) 0.69 (0.39e1.24) 0.45 (0.23e0.87) 0.33 (0.23e0.87)
p ¼ 0.4153 p ¼ 0.1053 p ¼ 0.0074 p ¼ 0.0015
Time to ﬁrst exacerbation, HR (95% CI) 0.23 (0.03e2.06) 0.21 (0.02e1.85) 0.23 (0.03e2.06) 0.25 (0.03e2.26)
p ¼ 0.0754 p ¼ 0.0592 p ¼ 0.0758 p ¼ 0.0919
Data expressed as mean (SE) unless otherwise stated; ACQ ¼ Asthma Control Questionnaire; AQLQ ¼ Asthma Quality of Life Questionnaire; AUC ¼ area under the curve;
CI ¼ conﬁdence interval; FEF ¼ forced expiratory ﬂow; FEV1 ¼ forced expiratory volume in 1 s; FP ¼ ﬂuticasone propionate; FVC ¼ forced vital capacity; HR ¼ hazard ratio;
PEF ¼ peak expiratory ﬂow; SE ¼ standard error.
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[7], although the potential role of DP1 remains controversial and
hence the likely clinical effects of dual inhibition of these receptors
is difﬁcult to predict. There has been 1 additional study of BI 671800
in asthma [9]. In a randomised, double-blind, placebo-controlled,
incomplete crossover study of 101 asthma patients also taking
inhaled ﬂuticasone (88 mg twice daily), 400 mg BI 671800 admin-
istered once daily or 200 mg administered twice daily was not
associated with improvement in FEV1 after 4 weeks of adminis-
tration. However, the dose in that study was only half that given in
the current Study 2 (800 mg). The results of the crossover study areTable 4
Secondary and exploratory endpoints after 6 weeks of treatment (Trial 2).
Comparison with placebo BI 671800 400 mg
twice daily
Montelukast 10 mg
once daily
ACQ score 0.28 (0.12) 0.18 (0.12)
p ¼ 0.0092 p ¼ 0.0732
FEV1 percent predicted AUC0e3h 3.75 (1.47) 2.27 (1.55)
p ¼ 0.0058 p ¼ 0.0715
FEV1 trough, L 0.14 (0.05) 0.08 (0.05)
p ¼ 0.0026 p ¼ 0.0671
FEV1 AUC0e3h, L 0.14 (0.05) 0.07 (0.05)
p ¼ 0.0028 p ¼ 0.0924
FVC trough, L 0.105 (0.062) 0.002 (0.066)
p ¼ 0.0471 p ¼ 0.4869
FEF25e75 trough, L/s 0.17 (0.07) 0.17 (0.08)
p ¼ 0.0125 p ¼ 0.0152
Morning PEF, L/min 3.76 (6.64) 9.01 (6.97)
p ¼ 0.2856 p ¼ 0.0985
Evening PEF, L/min 0.14 (5.94) 3.42 (6.25)
p ¼ 0.5096 p ¼ 0.2924
AQLQ score 0.09 (0.13) 0.09 (0.13)
p ¼ 0.2383 p ¼ 0.2535
Time to ﬁrst asthma worsening,
HR (95% CI)
0.75 (0.39e1.46) 1.00 (0.52e1.91)
p ¼ 0.2002 p ¼ 0.4940
Time to ﬁrst exacerbation,
HR (95% CI)
0.73 (0.12e4.39) 0.44 (0.05e4.22)
p ¼ 0.3668 p ¼ 0.2320
Data expressed as mean (SE) unless otherwise stated; ACQ ¼ Asthma Control
Questionnaire; AUC ¼ area under the curve; AQLQ ¼ Asthma Quality of Life Ques-
tionnaire; CI ¼ conﬁdence interval; FEF ¼ forced expiratory ﬂow; FEV1 ¼ forced
expiratory volume in 1 s; FVC ¼ forced vital capacity; HR ¼ hazard ratio; PEF ¼ peak
expiratory ﬂow; SE ¼ standard error.difﬁcult to interpret due to the lack of an active control group.
Finally, beneﬁt from BI 671800 treatment has also been reported in
allergic rhinitis patients: a reduction in nasal and ocular symptoms
in a nasal allergen challenge model [12]. Studies 1 and 2 contribute
signiﬁcantly to the body of evidence on this class of drug, and
provide further proof of concept for clinical improvement through
CRTH2 inhibition.
In summary, in our studies of the CRTH2 antagonist BI 671800 in
patients with asthma who were either controller-naïve or taking
ICS, which are the largest studies of a CRTH2 antagonism in asthma
patients to date, modest but statistically signiﬁcant increases in
FEV1 were observed in controller-naïve patients. These increases
were similar to that observed with the leukotriene receptor
antagonist, montelukast [9,13], and in subjects taking ICSBI 671800
appeared to produce an additional effect compared with ICS alone.
In addition, in post hoc sub group analyses, there was a trend to-
wards higher FEV1 responses in both studies in subjects with an
elevated peripheral blood eosinophil count. Thus, PGD2 inhibition
has potential as a treatment for patients with asthma not
adequately controlled with ICS alone. Further studies, preferably
with the more potent inhibitors of CRTH2 currently under devel-
opment, are warranted.Conﬂicts of interest
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